Coya Therapeutics, Inc.
About Coya Therapeutics, Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $7.9M
- Net income
- -$21.2M
- Total assets
- $50.0M
- Market cap
- $103.7M
- Operating margin
- -485.4%
- Net margin
- -418.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.6M
- Operating expenses
- $20.8M
- Operating income
- -$17.2M
- Income tax
- -$720.3K
- Net income
- -$14.9M
- EPS (basic)
- $-0.98
- EPS (diluted)
- $-0.98
Balance sheet
- Total assets
- $44.3M
- Current assets
- $44.3M
- Total liabilities
- $4.8M
- Current liabilities
- $3.8M
- Shareholders’ equity
- $39.6M
Cash flow
- Operating cash flow
- -$10.3M
- Investing cash flow
- -$25.0K
- Financing cash flow
- $16.0M
- Net cash flow
- $5.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $103.7M
- EPS (diluted)
- $-0.98
- Shares outstanding
- 23.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 29, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.2M in FY2025.
- Trading 40% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Coya Therapeutics, Inc..
Write a review
News about Coya Therapeutics, Inc.
News & sentiment via Polygon.io
